Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24585457
DOI
10.1002/mc.22141
Knihovny.cz E-resources
- Keywords
- Colorectal cancer, DNA instability, DNA repair, anti-cancer therapy, biomarker, follow-up study,
- MeSH
- Colon drug effects metabolism MeSH
- Colorectal Neoplasms blood drug therapy genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- DNA Repair * drug effects MeSH
- Antineoplastic Agents therapeutic use MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Rectum drug effects metabolism MeSH
- Aged MeSH
- Case-Control Studies MeSH
- DNA Breaks drug effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antineoplastic Agents MeSH
DNA repair in blood cells was observed to be suboptimal in cancer patients at diagnosis, including colorectal cancer (CRC). To explore the causality of this phenomenon, we studied the dynamics of DNA repair from diagnosis to 1 yr follow-up, and with respect to CRC treatment. Systemic CRC therapy is targeted to DNA damage induction and DNA repair is thus of interest. CRC patients were blood-sampled three times in 6-mo intervals, starting at the diagnosis, and compared to healthy controls. DNA repair was characterized by mRNA levels of 40 repair genes, by capacity of nucleotide excision repair (NER), and by levels of DNA strand breaks (SBs). NER and base excision repair genes were significantly under-expressed (P < 0.016) in patients at diagnosis compared to controls, in accordance with reduced NER function (P = 0.008) and increased SBs (P = 0.015). Six months later, there was an increase of NER capacity, but not of gene expression levels, in treated patients only. A year from diagnosis, gene expression profiles and NER capacity were significantly modified in all patients and were no longer different from those measured in controls. All patients were free of relapse at the last sampling, so we were unable to clarify the impact of DNA repair parameters on treatment response. However, we identified a panel of blood DNA repair-related markers discerning acute stage of the disease from the remission period. In conclusion, our results support a model in which DNA repair is altered as a result of cancer.
1st Faculty of Medicine Institute of Biology and Medical Genetics Prague Czech Republic
Biomedical Centre Medical School Pilsen Charles University Prague Pilsen Czech Republic
Faculty of Science Charles University Prague Czech Republic
Human Genetics Foundation Torino Italy
Institute of Biotechnology ASCR Prague Czech Republic
Institute of Experimental Medicine ASCR Prague Czech Republic
TATAA Biocenter Goteborg Sweden
Thomayer Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic
References provided by Crossref.org
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility